Pluri Inc. Secures New Patent From The China National Intellectual Property Administration For 3D Immune Cell Expansion And Activation Technology, Expanding Global IP Portfolio

Pluri Inc., a biotechnology company developing a collaborative network of ventures built on its proprietary cell-based technology platform, announced that the China National Intellectual Property Administration has granted a new patent to its wholly owned subsidiary, Pluri Biotech Ltd. The patent covers the company’s advanced 3D immune cell expansion and activation technology.

The newly issued patent, titled “System and Methods for Immune Cells Expansion and Activation in Large Scale” (Patent No. CN 119301238 B), expands Pluri’s global intellectual property portfolio, which already includes granted patents in the United States, Japan, Korea, Australia, and Israel. This broader protection supports the company’s strategy to pursue global collaborations and licensing agreements for immune cell therapy products developed on its automated, large-scale manufacturing platform.

The patent family covers large-scale production of multiple immune cell types, both unmodified and genetically engineered, for a wide range of therapeutic applications. The technology supports the expansion of cell types across lymphoid and myeloid lineages, including conventional and unconventional T cells such as MAIT cells, Natural Killer (NK) cells, Tumor-Infiltrating Lymphocytes (TILs), and engineered platforms using CAR and TCR constructs.

Securing patent protection in China comes at an important moment for the country’s rapidly growing cell therapy sector. China has become one of the world’s most active markets for CAR-T and advanced cell therapy development, supported by increasing clinical adoption, expanding manufacturing capacity, and rising investment. Strengthening the company’s intellectual property position in China enhances Pluri’s ability to participate in this fast-moving environment and contributes to its broader global strategy.

Pluri’s 3D expansion platform is designed to address key manufacturing challenges associated with traditional cell therapy production. The system uses a novel bioreactor that mimics the human lymph node environment to expand billions of immune cells at scale. This approach is expected to significantly reduce manufacturing costs—an essential requirement in high-volume markets such as China—while supporting rigorous quality control through a closed, automated process that ensures consistent batch quality and maintains cell integrity at industrial scale.

With protection now spanning the U.S., China, Japan, Korea, Australia, and Israel, the company aims to provide an “IP Bridge” for partners developing therapies on its platform across major global healthcare markets. This broad coverage creates a unified framework for international licensing and development, offering global pharmaceutical companies greater confidence when operating in China while also helping Chinese biotechnology firms pursue international expansion. By securing patents in both the China National Intellectual Property Administration and the U.S. Patent and Trademark Office, Pluri has strengthened cross-continental defensibility that may reduce partnering risks and support high-value collaborations focused on scalability, quality, and long-term commercial success.

Yaky Yanay, Chief Executive Officer and President of the company, said that obtaining patent protection in China affirms both the novelty and scalability of Pluri’s technology. He added that, together with granted patents in other major markets, the company aims to offer partners a globally protected platform capable of supporting large-scale immune cell production.